Compare Enveric Biosciences Inc (ENVB) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs ING Groep NV — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while ING Groep NV trades at $32.88 (market cap $94.33B). The key difference: ING Groep NV is far larger — about 17731.2× Enveric Biosciences Inc's market cap, and ING Groep NV pays a 3.8% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | ING | |
|---|---|---|
Market Cap | $5.32M | $94.33B |
Sector | Health | Financials |
52-Week High | $17.40 | $33.31 |
52-Week Low | $1.28 | $22.67 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
ING trades at $32.75, up 1.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows solid fundamentals with a P/E of 13.36, net income margin of 27.84%, and a consistent earnings beat history in recent quarters. Recent corporate developments include a new subscription banking model and a dividend announcement for H1-2026.
The outlook is positive with strong analyst support (62.5% Buy rating) and DCF analyses suggesting intrinsic value above current price. Key opportunities include European rate environment benefits and strategic diversification, while risks involve significant negative operating cash flows and sensitivity to macroeconomic conditions affecting the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
